ArticleInternational journal of general medicine2025
Nucleotide-Bound Oligomeric Domain-Like Receptor Protein 3 as a Serological Biomarker in Relation to Disease Severity and Delirium After Acute Pancreatitis: A Two-Center Prospective Cohort Study.
Article in International journal of general medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Acute pancreatitis (AP) is a very common infectious diseases, with delirium as a conventional complication. Nucleotide-binding oligomeric structural domain-like receptor protein 3 (NLRP3) is involved in inflammatory response after AP. We set out to determine whether serum NLRP3 levels are related to severity and delirium in patients with AP. Methods: In this two-center prospective cohort study, a total of 311 patients with AP were divided to study group and validation group according to the ratio of 2:1, and serum NLRP3 levels were measured in all patients and healthy controls. To assess disease severity, Acute Physiology and Chronic Health Evaluation II (APACHE II), Ranson and Sequential Organ Failure Assessment (SOFA) scores were recorded. Delirium was observed as an outcome variable. Multifactorial analysis was performed to discern severity correlations and outcome correlations. Prediction model containing independent predictors of delirium was constructed in study group and validated in validation group. Results: Serum NLRP3 levels were significantly higher in patients with AP than in controls, and were independently associated with three traditional indicators of AP severity, that is APACHE II scores, Ranson scores, and SOFA scores. When compared with the preceding traditional predictors, serum NLRP3 levels had comparable predictive ability for post-AP delirium. The four predictors were incorporated to create the predictive model of nomogram presentation. The model displayed significantly higher predictive capability than their use alone. In addition, the model was similarly effective for delirium prediction in validation group. Conclusion: Elevated serum NLRP3 levels after AP, in firm correlation with AP severity, independently predict in-hospital delirium, solidifying serum NLRP3 as a candidate for severity assessment and delirium anticipation after AP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.